Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence

Journal of Psychopharmacology

Volumn 29, Issue 1, 2015, Pages 15-23

  Cunill, R ^a   Castells, X ^b   Tobias, A ^c   Capella D ^b  

^a PARC SANITARI SANT JOAN DE DÉU   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c INSTITUTE OF ENVIRONMENTAL ASSESSMENT AND WATER RESEARCH   (Spain)

Author keywords

Attention deficit hyperactivity disorder; efficacy; meta analysis; safety; substance use disorder

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PEMOLINE; PLACEBO; CENTRAL STIMULANT AGENT;

ADVERSE OUTCOME; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADDICTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; META ANALYSIS; PSYCHIATRIC DIAGNOSIS; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84918500622     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114544777     Document Type: Article

References (68)

1. Washington, DC: American Psychiatric Association ; 1987 :
2. Washington, DC: American Psychiatric Association ; 1994:
3. Washington, DC: American Psychiatric Association ; 2000:
4. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 ; 50: 1088-1101
5. Berkey CS, Hoaglin DC, Mosteller F, et al. A random effects regression model for meta-analysis. Stat Med. 1995 ; 14: 395-411
6. Borenstein M, Hedges LV, Higgins JPT, et al Introduction to Meta-analysis. Borenstein M Hedges LV Higgins JPT, ed. Chichester: John Wiley ; 2009: 226-242.
7. Canadian ADHD Practice Guidelines, Third Edition. Toronto, Ontario: ; 2011:
8. Carpentier PJ, de Jong CA, Dijkstra BA, et al. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction. 2005 ; 100: 1868-1874
9. Castells X, Cunill R, Capellà D. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: A meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2013 ; 69: 347-356
10. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: A meta-regression analysis. CNS Drugs. 2011 ; 25: 157-169
11. Charach A, Yeung E, Climans T, et al. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: Comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011 ; 50: 9-21
12. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954 ; 10: 110-129
13. Collins SL, Levin FR, Foltin RW, et al. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 2006 ; 82: 158-167
14. Cunill R, Castells X, Tobias A, et al. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: A meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf. 2013 ; 22: 961-969
15. Da Costa BR, Nüesch E, Rutjes AW, et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: A meta-epidemiological study. J Clin Epidemiol. 2013 ; 66: 847-855
16. Dakwar E, Mahony A, Pavlicova M, et al. The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders. J Clin Psychiatry. 2012 ; 73: e1372 - e1378
17. Delavenne H, Duarte Garcia F, Lacoste J, et al. Psychosis in a cocaine-dependent patient with ADHD during treatment with methylphenidate. Gen Hosp Psychiatry. 2013 ; 35: 451.e7-9
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7: 177-188
19. Elbourne DR, Altman DG, Higgins JP, et al. Meta-analyses involving cross-over trials: Methodological issues. Int J Epidemiol. 2002 ; 31: 140-149
20. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004 ; 24: 24-29
21. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007 ; 190: 402-409
22. Harbord R, Higgins JPT. Meta-regression in Stata. Stata Journal. 2008 ; 8: 493-519
23. Harris R, Bradburn M, Deeks J, et al. Metan: Fixed- and random-effects meta-analysis. Stata Journal. 2008 ; 8: 3-28
24. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002 ; 67: 149-156
25. Higgins JPT, Green S Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0. Higgins JPT Green S, ed. The Cochrane Collaboration ; 2011a:
26. HigginsJPTGreenS (2011b) Re-expressing SMD by transformation to OR. In: HigginsJPTGreenS (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available at: www.cochrane-handbook.org
27. HigginsJPTGreenS (2011c) Methods for incorporating cross-over trials into a meta-analysis. In: HigginsJPTGreenS (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available at: www.cochrane-handbook.org
28. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. Brit Med J. 2003 ; 327: 557-560
29. Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: A meta-analysis. JAMA Psychiatry. 2013 ; 70: 740-749
30. Jasinski DR, Faries DE, Moore RJ, et al. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend. 2008 ; 95: 140-146
31. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: What do we know and why should we care?. Addiction. 2012 ; 107: 467-477
32. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006 ; 163: 716-723
33. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985 ; 142: 1259-1264
34. Kleber HD, Weiss RD, Anton RF, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 ; 164: 5-123
35. Koesters M, Becker T, Kilian R, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol. 2009 ; 23: 733-744
36. Kollins SH, English JS, Itchon-Ramos N, et al. A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD. J Atten Disord. 2014 ; 18: 158-168
37. Konstenius M, Jayaram-Lindström N, Beck O, et al. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend. 2010 ; 108: 130-133
38. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010 ; 10: 67
39. Lee SS, Humphreys KL, Flory K, et al. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review. Clin Psychol Rev. 2011 ; 31: 328-341
40. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: Double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006 ; 81: 137-148
41. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007 ; 87: 20-29
42. Mariani JJ, Levin FR. Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict. 2007 ; 16: 45-54
43. McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict. 2010 ; 19: 481-489
44. Molina BS, Hinshaw SP, Eugene Arnold L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013 ; 52: 250-263
45. National Institute for Health and Clinical Excellence (NICE) (2008) Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guideline 72. Available at: nice.org.uk/CG72 [NICE guideline]
46. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA. 2004 ; 291: 1887-1896
47. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007 ; 21: 10-41
48. Patrick KS, Straughn AB, Minhinnett RR, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2007 ; 81: 346-353
49. Perez de los Cobos J, Siñol N, Perez V, et al. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol. 2012 2012 ;:
50. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: A systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl). 2008 ; 197: 1-11
51. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 ; 46: 894-921
52. Riggs PD, Hall SK, Mikulich-Gilbertson SK, et al. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 2004 ; 43: 420-429
53. Riggs PD, Winhusen T, Davies RD, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011 ; 50: 903-914
54. Schubiner H. Substance abuse in patients with attention-deficit hyperactivity disorder: Therapeutic implications. CNS Drugs. 2005 ; 19: 643-655
55. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002 ; 10: 286-294
56. Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. Br J Psychiatry. 2009 ; 194: 204-211
57. Stata Statistical Software: Release 12. College Station, Texas: StataCorp LP ; 2011:
58. Szobot CM, Rohde LA, Katz B, et al. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res. 2008 ; 41: 250-257
59. Thurstone C, Riggs PD, Salomonsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry. 2010 ; 49: 573-582
60. Tirado CF, Goldman M, Lynch K, et al. Atomoxetine for treatment of marijuana dependence: A report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend. 2008 ; 94: 254-257
61. Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry. 2007 ; 68: 23-30
62. Urcelay GP, Dalley JW. Linking ADHD, impulsivity, and drug abuse: A neuropsychological perspective. Curr Top Behav Neurosci. 2012 ; 9: 173-197
63. Van Emmerik-van Oortmerssen K, Van de Glind G, Van den Brink W, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012 ; 122: 11-19
64. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: The nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004 ; 27: 283-301
65. Wilens TE, Adamson J, Sgambati S, et al. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am Addict. 2007 ; 16: 14-21
66. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008a ; 47: 21-31
67. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008b ; 96: 145-154
68. Winhusen TM, Somoza EC, Brigham GS, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010 ; 71: 1680-1688